Format

Send to

Choose Destination
Kidney Blood Press Res. 2007;30(5):314-22. Epub 2007 Jul 11.

Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study.

Author information

1
Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden. bengt.fellstrom@medsci.uu.se

Abstract

BACKGROUND:

Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD).

AIMS:

AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events) is the first large-scale international trial to assess the effects of statins on cardiovascular outcomes in patients with ESRD on chronic haemodialysis. Preliminary baseline data from the randomised population are presented.

METHODS:

A total of 2,775 patients from 280 centres in 25 countries were randomised into the study. Patients aged 50-80 years on regular chronic haemodialysis for at least 3 months before screening were eligible for inclusion. They were randomised 1:1 to receive either rosuvastatin 10 mg or placebo daily and assessed throughout the study.

RESULTS:

The mean age at baseline was 64 years. Most patients were male (62%) and 85% were white. The median time since commencing renal replacement was 32 months. Mean total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were 4.53 mmol/l (175 mg/dl) and 2.57 mmol/l (99 mg/dl), respectively.

CONCLUSION:

Results from the AURORA trial will impact on the current guidelines and use of statins in this patient population.

PMID:
17671394
PMCID:
PMC2790755
DOI:
10.1159/000106803
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center